Fig. 1: Treatment algorithm for newly-diagnosed acute myeloid leukemia in patients unfit for intensive therapies.
From: Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
Targeted inhibitors = FLT3, IDH1/2 or menin inhibitor. Ven-Venetoclax, HMA- hypomethylating agent- azacitidine or decitabine. *C.D.D. prefers ivosidenib-azacitidine over Ven-HMA in IDH1MUT. $excluding NPM1MUT.
